Dual-Time-Point Posttherapy 177 Lu-PSMA-617 SPECT/CT Describes the Uptake Kinetics of mCRPC Lesions and Prognosticates Patients’ Outcome
Journal of Nuclear Medicine · 2023-09 · 64 (9) · 1431-1438
DOI: 10.2967/jnumed.122.264770 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 06.07.2023. Verfasst von Manuela Straub und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine and Clinical Molecular Imaging, University Hospital, Tübingen, Germany. Hauptthemen laut MEDLINE: Prostate-Specific Antigen, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Abstract (Originalsprache)
177Lu-PSMA-617 is an effective therapeutic option in metastasized castration-resistant prostate cancer (mCRPC). However, some patients progress under treatment. We hypothesized that the tracer kinetics within the metastases may influence the therapy effectiveness and tested this hypothesis by analyzing uptake parameters on 2 consecutive posttherapy SPECT/CT scans. Methods: mCRPC patients treated with 177Lu-PSMA-617 and with available posttherapy SPECT/CT imaging (24 and 48 h after the first treatment) were enrolled retrospectively. Volumes of interest were defined on lymph node metastasis (LNM) and bone metastasis (BM) on both SPECT/CT scans. The reduction of the percentage injected dose (%IDred) between the 2 SPECT/CT scans was computed. We compared %IDred of responders (prostate-specific antigen drop ≥ 50% after 2 cycles of 177Lu-PSMA-617) and nonresponders. We tested the association of %IDred with progression-free survival and overall survival (OS) using a univariate Kaplan-Meier (KM) analysis and a multivariate Cox regression model.
Results
Fifty-five patients (median age, 73 y; range, 54-87 y) were included. %IDred in LNM and BM was greater in nonresponders than in responders (for LNM, 36% in nonresponders [interquartile range (IQR), 26%-47%] vs. 24% in responders [IQR, 12%-33%] [P = 0.003]; for BM, 35% in nonresponders [IQR, 27%-52%] vs. 18% in responders [IQR, 15%-29%] [P = 0.002]). For progression-free survival, in KM analysis, greater %IDred in LNM (P = 0.008) and BM (P = 0.001) was associated with shorter survival, whereas in multivariate analysis, only %IDred in LNM was retained (P = 0.03). In univariate KM analysis of OS, greater %IDred in BM was associated with shorter survival (P = 0.002). In multivariate OS analysis, BM %IDred (P = 0.009) was retained.
Conclusion
The 177Lu-PSMA-617 clearance rate from mCRPC metastases appears to be a relevant prognosticator of response and survival, with faster clearing possibly signaling a shorter radiopharmaceutical residence time and absorbed dose. Dual-time-point analysis appears to be a feasible and readily available approach to estimate the likelihood of response and patients' survival.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine and Clinical Molecular Imaging, University Hospital, Tübingen, Germany.
- Institute of Clinical Epidemiology and Applied Biometry, University of Tübingen, Tübingen, Germany.
- Department of Radiology, University Hospital, Tübingen, Germany.
- Department of Nuclear Medicine and Clinical Molecular Imaging, University Hospital, Tübingen, Germany; christian.lafougere@med.uni-tuebingen.de.
- Cluster of Excellence 2180 "Image-Guided and Functionally Instructed Tumor Therapies," Eberhard Karls University, Tübingen, Germany.
- German Cancer Consortium, German Cancer Research Center Partner Site Tübingen, Tübingen, Germany; and.
Zitieren
APA
Straub, M., Kupferschläger, J., Serna Higuita, L. M., Weissinger, M., Dittmann, H., la Fougère, C., & Fiz, F. (2023). Dual-Time-Point Posttherapy 177 Lu-PSMA-617 SPECT/CT Describes the Uptake Kinetics of mCRPC Lesions and Prognosticates Patients’ Outcome. Journal of Nuclear Medicine, 64(9), 1431-1438. https://doi.org/10.2967/jnumed.122.264770
Vancouver
Straub M, Kupferschläger J, Serna Higuita LM, Weissinger M, Dittmann H, la Fougère C, et al. Dual-Time-Point Posttherapy 177 Lu-PSMA-617 SPECT/CT Describes the Uptake Kinetics of mCRPC Lesions and Prognosticates Patients’ Outcome. Journal of Nuclear Medicine. 2023;64(9):1431-1438. doi:10.2967/jnumed.122.264770
BibTeX
@article{Straub2023,
author = {Straub, Manuela and Kupferschläger, Jürgen and Serna Higuita, Lina Maria and Weissinger, Matthias and Dittmann, Helmut and la Fougère, Christian and Fiz, Francesco},
title = {Dual-Time-Point Posttherapy 177 Lu-PSMA-617 SPECT/CT Describes the Uptake Kinetics of mCRPC Lesions and Prognosticates Patients’ Outcome},
journal = {Journal of Nuclear Medicine},
year = {2023},
volume = {64},
number = {9},
pages = {1431--1438},
doi = {10.2967/jnumed.122.264770}
}
EUVIMED